CoChat

MicroRNA-210 Regulates Mitochondrial Free Radical Response to Hypoxia and Krebs Cycle in Cancer Cells by Targeting Iron Sulfur Cluster Protein ISCU

Open access

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Hypoxia in cancers results in the upregulation of hypoxia inducible factor 1 (HIF-1) and a microRNA, hsa-miR-210 (miR-210) which is associated with a poor prognosis. METHODS AND FINDINGS: In human cancer cell lines and tumours, we found that miR-210 targets the mitochondrial iron sulfur scaffold protein ISCU, required for assembly of iron-sulfur clusters, cofactors for key enzymes involved in the Krebs cycle, electron transport, and iron metabolism. Down regulation of ISCU was the major cause of induction of reactive oxygen species (ROS) in hypoxia. ISCU suppression reduced mitochondrial complex 1 activity and aconitase activity, caused a shift to glycolysis in normoxia and enhanced cell survival. Cancers with low ISCU had a worse prognosis. CONCLUSIONS: Induction of these major hallmarks of cancer show that a single microRNA, miR-210, mediates a new mechanism of adaptation to hypoxia, by regulating mitochondrial function via iron-sulfur cluster metabolism and free radical generation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0010345

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 MiR-210 regulates ISCU expression in MCF7 cells. A, miR-210 increases under hypoxia, with the most robust induction seen at 48 hrs with 0.1% oxygen. B, under the same conditions, the strongest downregulation of ISCU mRNA is observed at 48 hrs with 0.1% oxygen. The expression levels of miR-210 and ISCU mRNA under hypoxia are relative to their normoxic expression levels at 24 hrs (N). Mean ± s.e.m. of three independent experiments is shown (* p<0.05, ** p<0.01, *** p<0.001). C, transfection of anti-210 partially rescues the hypoxic suppression of ISCU mRNA and mimic-210 overexpression decreases ISCU mRNA in normoxia at 48 hrs. Expression of ISCU mRNA is relative to the anti-ctrl in normoxia (N). Mean ± s.e.m. of three independent experiments is shown (** p<0.01, *** p<0.001). D, (top panel) ISCU protein is downregulated in MCF7 lysates at 0.1% oxygen compared to normoxic lysates (N) when the anti-ctrl is transfected for 48 hrs. This decrease in protein level under hypoxic conditions is partially rescued when the anti-210 is transfected. Under normoxic conditions, mimic-210 suppresses ISCU protein levels compared to mimic-ctrl transfected cells. D, (bottom panel), quantification of the rescue of ISCU protein level upon transfection of anti-210. Transfection of anti-210 rescues the ISCU protein levels in MCF7 by approximately 40%. Mean ± S.E.M of two independent experiments is shown. (* p<0.05).
Figure 1 MiR-210 regulates ISCU expression in MCF7 cells. A, miR-210 increases under hypoxia, with the most robust induction seen at 48 hrs with 0.1% oxygen. B, under the same conditions, the strongest downregulation of ISCU mRNA is observed at 48 hrs with 0.1% oxygen. The expression levels of miR-210 and ISCU mRNA under hypoxia are relative to their normoxic expression levels at 24 hrs (N). Mean ± s.e.m. of three independent experiments is shown (* p<0.05, ** p<0.01, *** p<0.001). C, transfection of anti-210 partially rescues the hypoxic suppression of ISCU mRNA and mimic-210 overexpression decreases ISCU mRNA in normoxia at 48 hrs. Expression of ISCU mRNA is relative to the anti-ctrl in normoxia (N). Mean ± s.e.m. of three independent experiments is shown (** p<0.01, *** p<0.001). D, (top panel) ISCU protein is downregulated in MCF7 lysates at 0.1% oxygen compared to normoxic lysates (N) when the anti-ctrl is transfected for 48 hrs. This decrease in protein level under hypoxic conditions is partially rescued when the anti-210 is transfected. Under normoxic conditions, mimic-210 suppresses ISCU protein levels compared to mimic-ctrl transfected cells. D, (bottom panel), quantification of the rescue of ISCU protein level upon transfection of anti-210. Transfection of anti-210 rescues the ISCU protein levels in MCF7 by approximately 40%. Mean ± S.E.M of two independent experiments is shown. (* p<0.05).CC BY · PubMed Central
Figure 2 MiR-210 negatively regulates aconitase and complex I activity in MCF7 and HCT116, and upregulates glycolysis. Cells transfected with siRNA against ISCU or with mimic-210 show a significant decrease in the activity of the Fe-S protein aconitase (A) and complex I (B) at 48 hrs. Activity is expressed relative to scr for siISCU3 or to mimic-ctrl for mimic-210. Mean ± s.e.m. of three independent experiments is shown (* p<0.05, ** p<0.01, *** p<0.001). C, hypoxia decreases aconitase and complex I activity in MCF7 and HCT116. Activity is expressed relative to normoxia (N). Transfection of MCF7 with anti-210 increases the level of aconitase activity, compared to anti-ctrl. Mean ± s.e.m. of three independent experiments is shown (* p<0.05, ** p<0.01, *** p<0.001). D, in normoxia, MCF7 transfected with mimic-210 have an increase in the secreted lactate concentration and a reduction in the extracellular pyruvate after 48 hours. Lactate: Pyruvate ratio shows a significant increase under the same conditions. Transfection with anti-210 in hypoxia reduced lactate production compared to anti-ctrl transfected cells. Mean ± s.e.m. of three biological replicates is shown (* p<0.05, ** p<0.01, *** p<0.001).
Figure 2 MiR-210 negatively regulates aconitase and complex I activity in MCF7 and HCT116, and upregulates glycolysis. Cells transfected with siRNA against ISCU or with mimic-210 show a significant decrease in the activity of the Fe-S protein aconitase (A) and complex I (B) at 48 hrs. Activity is expressed relative to scr for siISCU3 or to mimic-ctrl for mimic-210. Mean ± s.e.m. of three independent experiments is shown (* p<0.05, ** p<0.01, *** p<0.001). C, hypoxia decreases aconitase and complex I activity in MCF7 and HCT116. Activity is expressed relative to normoxia (N). Transfection of MCF7 with anti-210 increases the level of aconitase activity, compared to anti-ctrl. Mean ± s.e.m. of three independent experiments is shown (* p<0.05, ** p<0.01, *** p<0.001). D, in normoxia, MCF7 transfected with mimic-210 have an increase in the secreted lactate concentration and a reduction in the extracellular pyruvate after 48 hours. Lactate: Pyruvate ratio shows a significant increase under the same conditions. Transfection with anti-210 in hypoxia reduced lactate production compared to anti-ctrl transfected cells. Mean ± s.e.m. of three biological replicates is shown (* p<0.05, ** p<0.01, *** p<0.001).CC BY · PubMed Central
Figure 3 MiR-210 increases the formation of ROS in MCF7 and HCT116 cell lines. A, in normoxia, transfection of mimic-210 significantly increases superoxide production at 48 hrs as measured by MitoSox staining. Representative images from mimic-210 transfected cells are shown on the top panels and the mean ± s.e.m. of approximately 300 cells are shown on the bottom panels (***, p<0.001). B, exposure of cells to 0.1% oxygen for 48 hrs enhances the production of superoxide; this effect is almost completely reversed upon transfection of anti-210. Representative images from miR-210 transfected are shown on the left panels and the mean ± s.e.m. of approximately 300 cells are shown on the right panels (***, p<0.001). C, ROS production induced by mimic-210 is inhibited in MCF7 cells by cotrasfection with the ISCU2 expressing plasmid. Mean ± s.e.m. of approximately 300 cells is shown (*** p<0.001). Bars = 10 µm.
Figure 3 MiR-210 increases the formation of ROS in MCF7 and HCT116 cell lines. A, in normoxia, transfection of mimic-210 significantly increases superoxide production at 48 hrs as measured by MitoSox staining. Representative images from mimic-210 transfected cells are shown on the top panels and the mean ± s.e.m. of approximately 300 cells are shown on the bottom panels (***, p<0.001). B, exposure of cells to 0.1% oxygen for 48 hrs enhances the production of superoxide; this effect is almost completely reversed upon transfection of anti-210. Representative images from miR-210 transfected are shown on the left panels and the mean ± s.e.m. of approximately 300 cells are shown on the right panels (***, p<0.001). C, ROS production induced by mimic-210 is inhibited in MCF7 cells by cotrasfection with the ISCU2 expressing plasmid. Mean ± s.e.m. of approximately 300 cells is shown (*** p<0.001). Bars = 10 µm.CC BY · PubMed Central
Figure 4 MiR-210 affects cell survival and is inversely correlated to ISCU in hypoxic tumor xenografts. A, apoptosis (Annexin V+ cells) was measured in MCF7 (left) and HCT116 (right) cells treated with miR-210 inhibitor or mimic, after 48 hours exposure to 0.1% oxygen or normoxia. Mean ± s.e.m. is representative of 3 independent experiments (* p<0.05, ** p<0.01, *** p<0.001). B, after transfecting MCF7 cells with scrambled LNA or mir-210 LNA and exposed to 0.1% oxygen or normoxia (48 hrs), the cells were re-plated (100 and 500 cells/well). After a 12-day incubation, colonies were fixed, stained, and the surviving fractions were calculated based upon the plating efficiency. C, surviving fractions were calculated as in (B) in HeLa cells, which were transfected with anti-ctrl or anti-210 (Applied Biosystems/Ambion, Austin, TX, USA) and exposed to 0.01% oxygen or normoxia. In all colony assays, mean ± s.e.m. is representative of 2 independent experiments carried out in triplicate employing 2 different plating densities. (** p<0.01, *** p<0.001). D, RT-PCR for ISCU and miR-210 in U87 xenografts treated with anti-angiogenic therapy (bevacizumab). Relative expression of ISCU normalised to β-actin, miR-210 normalised to three small nucleolar controls, RNU43, RNU44 and RNU48. Mean expression ± s.e.m. in 4 animals/group is shown (** p<0.01, ***p<0.001).
Figure 4 MiR-210 affects cell survival and is inversely correlated to ISCU in hypoxic tumor xenografts. A, apoptosis (Annexin V+ cells) was measured in MCF7 (left) and HCT116 (right) cells treated with miR-210 inhibitor or mimic, after 48 hours exposure to 0.1% oxygen or normoxia. Mean ± s.e.m. is representative of 3 independent experiments (* p<0.05, ** p<0.01, *** p<0.001). B, after transfecting MCF7 cells with scrambled LNA or mir-210 LNA and exposed to 0.1% oxygen or normoxia (48 hrs), the cells were re-plated (100 and 500 cells/well). After a 12-day incubation, colonies were fixed, stained, and the surviving fractions were calculated based upon the plating efficiency. C, surviving fractions were calculated as in (B) in HeLa cells, which were transfected with anti-ctrl or anti-210 (Applied Biosystems/Ambion, Austin, TX, USA) and exposed to 0.01% oxygen or normoxia. In all colony assays, mean ± s.e.m. is representative of 2 independent experiments carried out in triplicate employing 2 different plating densities. (** p<0.01, *** p<0.001). D, RT-PCR for ISCU and miR-210 in U87 xenografts treated with anti-angiogenic therapy (bevacizumab). Relative expression of ISCU normalised to β-actin, miR-210 normalised to three small nucleolar controls, RNU43, RNU44 and RNU48. Mean expression ± s.e.m. in 4 animals/group is shown (** p<0.01, ***p<0.001).CC BY · PubMed Central
Figure 5 ISCU suppression is associated to miR-210 over-expression and relapse-free survival in breast cancer and HNSCC. A, miR-210 qPCR expression (DDCT) plotted as a function of ISCU mRNA expression (Illumina arrays) in the Oxford breast cancer series (left), and, relapse free survival for samples with high ISCU and low ISCU split by median in the Oxford breast cancer series (right). B, mRNA expression of the transcript hosting the miR-210 precursor plotted as a function of ISCU mRNA expression measure by Affymetrix U133b and U133a respectively in the Uppsala breast cancer series (left), and relapse free survival for samples with high ISCU and low ISCU split by median in the Uppsala breast cancer series (right). C, miR-210 qPCR expression (DDCT) plotted as a function of ISCU mRNA expression (Affymetrix arrays) in the Oxford-Manchester HNSCC cancer series where ISCU was initially found to be associated to hypoxia (left), and relapse free survival for samples with high ISCU and low ISCU split by median value in the Chung et al. HNSCC series (right).
Figure 5 ISCU suppression is associated to miR-210 over-expression and relapse-free survival in breast cancer and HNSCC. A, miR-210 qPCR expression (DDCT) plotted as a function of ISCU mRNA expression (Illumina arrays) in the Oxford breast cancer series (left), and, relapse free survival for samples with high ISCU and low ISCU split by median in the Oxford breast cancer series (right). B, mRNA expression of the transcript hosting the miR-210 precursor plotted as a function of ISCU mRNA expression measure by Affymetrix U133b and U133a respectively in the Uppsala breast cancer series (left), and relapse free survival for samples with high ISCU and low ISCU split by median in the Uppsala breast cancer series (right). C, miR-210 qPCR expression (DDCT) plotted as a function of ISCU mRNA expression (Affymetrix arrays) in the Oxford-Manchester HNSCC cancer series where ISCU was initially found to be associated to hypoxia (left), and relapse free survival for samples with high ISCU and low ISCU split by median value in the Chung et al. HNSCC series (right).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 45 references

Cited by

Items 201–300 of 326

Metadata

Authors
Favaro, E., Ramachandran, A., McCormick, R., Gee, H., Blancher, C., Crosby, M., Devlin, C., Blick, C., Buffa, F., Li, J.-L., Vojnovic, B., Pires das Neves, R., Glazer, P., Iborra, F., Ivan, M., Ragoussis, J., & Harris, A. L.
Affiliations
  • Centre for Human Genetics (GB)
  • John Radcliffe Hospital (GB)
  • Yale University (US)
  • Indiana University Indianapolis (US)
  • University of Oxford (GB)
Corresponding author
  • Ivan, Mircea
  • Harris, Adrian L.
Venue
PLoS ONE
Published
2010-04-26
Volume
5
Issue
4
Pages
e10345
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2044291869
Cited by
324
References
46
Citations by year
2026: 7 · 2025: 9 · 2024: 7 · 2023: 12 · 2022: 12 · 2021: 33 · 2020: 14 · 2019: 20 · 2018: 11 · 2017: 23 · 2016: 14 · 2015: 17 · 2014: 30 · 2013: 45 · 2012: 33
FWCI
11.59
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (publishedVersion, other-oa)
  • PEARL (University of Plymouth) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Archivio istituzionale della Ricerca - Bocconi (submittedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • Purdue University Indianapolis (Indiana University) (submittedVersion, cc-by)
  • Publisher
Funders
  • Alliance for Cancer Gene Therapy
  • Elsa U. Pardee Foundation
  • Wellcome Trust
  • Cancer Research UK
  • National Institute for Health and Care Research
  • University of Oxford
  • European Commission
  • Fondazione Italiana per la Ricerca sul Cancro
  • Urology Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
miR-210, IscU, iron-sulfur cluster assembly, hypoxia, reactive oxygen species, TCA cycle, mitochondrial complex I, aconitase, HIF-1, tumor cell survival, prognosis, iron metabolism, microRNA target regulation
MeSH terms
Hypoxia, Citric Acid Cycle, Free Radicals, Humans, Iron-Sulfur Proteins, Mitochondria, Neoplasms, Prognosis, MicroRNAs, Electron Transport Complex I, Cell Line, Tumor, Hypoxia-Inducible Factor 1, alpha Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.